Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2023-06-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于全资子公司收到药品一致性评价受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (867 characters) from a company about its wholly-owned subsidiary receiving a drug consistency evaluation acceptance notice from the National Medical Products Administration. It details the acceptance of a regulatory application for a pharmaceutical product and includes risk warnings and a statement of disclosure compliance. There are no financial statements, no detailed financial data, no management discussion of financial results, nor is it a transcript or presentation. The document is an official announcement of a regulatory event related to product approval, not a report or detailed filing. It is not a report publication announcement since it does not mention a report being attached or published. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-06-16 Chinese
关于全资子公司收到药品注册受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving a drug registration acceptance notice from the National Medical Products Administration. It details the drug name, registration application, market data, and risk warnings. The document is short (1098 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is not a report itself but an announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-07 Chinese
关于控股股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the partial release of pledged shares by a controlling shareholder. It details the number of shares released from pledge, the shareholder's total pledged shares, and risk warnings. There are no financial statements, earnings data, or management discussions. The content focuses on share pledge status and shareholder shareholding changes. This fits the category of a Major Shareholding Notification, as it reports changes in significant share ownership or share pledge status by a major shareholder.
2023-06-02 Chinese
关于亿帆医药股份有限公司2022年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 Annual General Meeting (AGM) of Yifan Pharmaceutical Co., Ltd. It details the procedures for convening and holding the AGM, the qualifications of attendees, the voting procedures, and the results of the votes on various proposals including the 2022 annual report, financial statements, profit distribution plan, and other corporate matters. The document is not the annual report itself but a legal opinion on the AGM and its resolutions. It includes detailed voting results and confirms the legality and validity of the meeting and its decisions. This type of document fits the category of AGM Information (AGM-R), as it relates to materials shared or produced in connection with the AGM, specifically a legal opinion on the AGM proceedings and outcomes. The document length (5894 characters) and content confirm it is a substantive legal opinion rather than a brief announcement or certification. Therefore, the correct classification is AGM Information (AGM-R).
2023-06-02 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2022 Annual General Meeting (AGM) resolution announcement for Yifan Pharmaceutical Co., Ltd. It details the date, attendance, voting results on various proposals including the 2022 annual report, financial statements, profit distribution plan, auditor appointment, and other corporate matters. The document is a formal announcement of the voting results and resolutions passed at the AGM, including legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves, but rather the outcomes of the shareholder meeting where these were approved. The document length is about 4813 characters, which is consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-06-02 Chinese
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder, including detailed information about the number of shares pledged, the proportion of shares, pledge start and end dates, and risk warnings. It does not contain financial statements, earnings data, or management discussion. It is a regulatory disclosure about share pledging activity, which fits the category of a Regulatory Filing (RNS) as it is a compliance announcement related to share pledging by a major shareholder, not a financial report or capital change announcement.
2023-05-31 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.